Historical Valuation
Xenetic Biosciences Inc (XBIO) is now in the Fair zone, suggesting that its current forward PS ratio of 1.67 is considered Fairly compared with the five-year average of -2.90. The fair price of Xenetic Biosciences Inc (XBIO) is between 1.70 to 3.30 according to relative valuation methord.
Relative Value
Fair Zone
1.70-3.30
Current Price：2.19
Fair
P/E
EV/EBITDA
EV/EBIT
P/S
P/OCF
P/FCF
1Y
3Y
5Y
Trailing
Forward
Xenetic Biosciences Inc (XBIO) has a current Price-to-Book (P/B) ratio of 0.84. Compared to its 3-year average P/B ratio of 0.76 , the current P/B ratio is approximately 9.93% higher. Relative to its 5-year average P/B ratio of 0.93, the current P/B ratio is about -10.10% higher. Xenetic Biosciences Inc (XBIO) has a Forward Free Cash Flow (FCF) yield of approximately -55.18%. Compared to its 3-year average FCF yield of -60.25%, the current FCF yield is approximately -8.42% lower. Relative to its 5-year average FCF yield of -51.45% , the current FCF yield is about 7.25% lower.
P/B
Median3y
0.76
Median5y
0.93
FCF Yield
Median3y
-60.25
Median5y
-51.45
Competitors Valuation Multiple
AI Analysis for XBIO
The average P/S ratio for XBIO competitors is 0.74, providing a benchmark for relative valuation. Xenetic Biosciences Inc Corp (XBIO.O) exhibits a P/S ratio of 1.67, which is 125.19% above the industry average. Given its robust revenue growth of 67.19%, this premium appears sustainable.
Performance Decomposition
AI Analysis for XBIO
1Y
3Y
5Y
Market capitalization of XBIO increased by 0.00% over the past 1 year. The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.
The secondary factor is the Unknown, contributed 0.00%to the performance.
Overall, the performance of XBIO in the past 1 year is driven by Unknown.
People Also Watch
Frequently Asked Questions
Is XBIO currently overvalued or undervalued?
Xenetic Biosciences Inc (XBIO) is now in the Fair zone, suggesting that its current forward PS ratio of 1.67 is considered Fairly compared with the five-year average of -2.90. The fair price of Xenetic Biosciences Inc (XBIO) is between 1.70 to 3.30 according to relative valuation methord.
What is Xenetic Biosciences Inc (XBIO) fair value?
XBIO's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average , adjusted by weights. The fair price of Xenetic Biosciences Inc (XBIO) is between 1.70 to 3.30 according to relative valuation methord.
How does XBIO's valuation metrics compare to the industry average?
The average P/S ratio for XBIO's competitors is 0.74, providing a benchmark for relative valuation. Xenetic Biosciences Inc Corp (XBIO) exhibits a P/S ratio of 1.67, which is 125.19% above the industry average. Given its robust revenue growth of 67.19%, this premium appears sustainable.
What is the current P/B ratio for Xenetic Biosciences Inc (XBIO) as of Jan 09 2026?
As of Jan 09 2026, Xenetic Biosciences Inc (XBIO) has a P/B ratio of 0.84. This indicates that the market values XBIO at 0.84 times its book value.
What is the current FCF Yield for Xenetic Biosciences Inc (XBIO) as of Jan 09 2026?
As of Jan 09 2026, Xenetic Biosciences Inc (XBIO) has a FCF Yield of -55.18%. This means that for every dollar of Xenetic Biosciences Inc’s market capitalization, the company generates -55.18 cents in free cash flow.
What is the current Forward P/E ratio for Xenetic Biosciences Inc (XBIO) as of Jan 09 2026?
As of Jan 09 2026, Xenetic Biosciences Inc (XBIO) has a Forward P/E ratio of -0.72. This means the market is willing to pay $-0.72 for every dollar of Xenetic Biosciences Inc’s expected earnings over the next 12 months.
What is the current Forward P/S ratio for Xenetic Biosciences Inc (XBIO) as of Jan 09 2026?
As of Jan 09 2026, Xenetic Biosciences Inc (XBIO) has a Forward P/S ratio of 1.67. This means the market is valuing XBIO at $1.67 for every dollar of expected revenue over the next 12 months.